Karyopharm Therapeutics traded at $5.31 this Tuesday July 5th, increasing $0.58 or 12.26 percent since the previous trading session. Looking back, over the last four weeks, Karyopharm Therapeutics gained 7.17 percent. Over the last 12 months, its price fell by 47.48 percent. Looking ahead, we forecast Karyopharm Therapeutics to be priced at 4.60 by the end of this quarter and at 4.24 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,862.00 24.00 0.63% 4.80%
AbbVie 153.93 0.13 0.08% 33.01%
Abbott 109.30 -0.92 -0.83% -8.01%
Amgen 246.73 1.18 0.48% 1.26%
Avrobio Inc 0.94 0.02 1.98% -88.96%
AstraZeneca 10,918.00 118.00 1.09% 26.10%
Astrazeneca 65.51 -0.44 -0.67% 9.37%
BioCryst Pharmaceuticals 11.14 0.30 2.77% -31.36%
Bristol-Myers Squibb 75.96 -0.88 -1.15% 13.97%
Enanta Pharmaceuticals 52.68 3.05 6.15% 20.49%
Epizyme 1.48 0 0% -80.60%
GlaxoSmithKline 1,786.64 0.04 0.002% 24.33%
Incyte Corp 79.25 1.58 2.03% -4.91%
J&J 178.14 -1.38 -0.77% 6.05%
Karyopharm Therapeutics 5.31 0.58 12.26% -47.48%
Eli Lilly 327.18 2.47 0.76% 38.98%
MacroGenics 3.31 0.26 8.52% -88.38%
Merck & Co 92.64 0.22 0.24% 18.60%
Mirati Therapeutics 71.96 0.78 1.10% -56.07%
Nektar Therapeutics 3.93 0.18 4.80% -76.76%
Novartis 81.33 0.42 0.52% -4.28%
Novartis 84.28 -0.08 -0.09% -7.97%
Pfizer 51.64 -0.67 -1.28% 31.43%
Ultragenyx Pharmaceutical 63.80 1.15 1.84% -30.21%
Regeneron Pharmaceuticals 596.56 1.16 0.19% 2.46%
Roche Holding 323.10 4.10 1.29% -9.23%
Sangamo BioSciences 4.67 0.39 9.11% -58.49%
TG Therapeutics 5.25 0.68 14.88% -86.49%
Xencor 30.45 1.59 5.51% -11.84%

Indexes Price Day Year
USND 11322 194.39 1.75% -22.79%
US2000 1741 13.57 0.79% -23.44%

Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.